Media headlines about Illumina (NASDAQ:ILMN) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Illumina earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the life sciences company an impact score of 46.8533841447358 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Hot Stock’s Watch List – Illumina Inc (NASDAQ: ILMN) – Stocks Pen (stockspen.com)
- Square Is One of 4 Upset Picks in Our Latest ‘Sweet 16’ Stock Selections – TheStreet.com (realmoney.thestreet.com)
- Is technical analysis on Illumina, Inc. (ILMN) is useful? – Wall Street Morning (wallstreetmorning.com)
- Illumina Just Hit an All-Time High: Buy, Sell, or Hold? – Motley Fool (fool.com)
Illumina (NASDAQ:ILMN) traded up $3.92 during mid-day trading on Tuesday, reaching $252.65. 589,555 shares of the company traded hands, compared to its average volume of 924,189. Illumina has a 1 year low of $162.35 and a 1 year high of $256.64. The stock has a market cap of $37,324.77, a P/E ratio of 50.94, a price-to-earnings-growth ratio of 3.36 and a beta of 0.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The firm had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. During the same quarter in the prior year, the firm earned $0.85 EPS. Illumina’s revenue for the quarter was up 25.7% on a year-over-year basis. research analysts anticipate that Illumina will post 4.59 EPS for the current year.
Several brokerages have recently weighed in on ILMN. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. Deutsche Bank set a $275.00 price objective on shares of Illumina and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Cowen boosted their price objective on shares of Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Monday, January 22nd. Leerink Swann boosted their price objective on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley boosted their price objective on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $241.39.
In other Illumina news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $217.38, for a total value of $271,725.00. Following the transaction, the director now directly owns 8,838 shares of the company’s stock, valued at approximately $1,921,204.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $223.40, for a total transaction of $4,468,000.00. Following the completion of the transaction, the director now directly owns 463,436 shares in the company, valued at $103,531,602.40. The disclosure for this sale can be found here. Insiders sold a total of 53,137 shares of company stock worth $12,263,490 over the last three months. 0.89% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/illumina-ilmn-given-media-impact-rating-of-0-18.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.